Adicet Bio, Inc. — Director's Dealing 2020

Sep 18, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adicet Bio, Inc. (ACET)
CIK: 0001720580
Period of Report: 2020-09-15

Reporting Person: Chimovits Erez (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
No securities are beneficially owned	0	Indirect

Footnotes

F1: The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") and OrbiMed Advisors Israel II Limited ("OrbiMed Israel II") on the Issuer's board of directors. The reportable securities are owned by OrbiMed Israel Partners Limited Partnership ("OIP") and OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP and OrbiMed Israel GP is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held by OIP. OrbiMed Israel GP II, L.P. ("OrbiMed Israel GP II") is the general partner of OIP II and OrbiMed Israel II is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held by OIP II.

F2: OrbiMed Israel GP and OrbiMed Israel II exercise the investment and voting power described in footnote 1 through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP and OIP II.

F3: Each of the Reporting Person, OrbiMed Israel GP, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Israel GP, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.